News Journal WatchAsk the Experts
Interview
Conference Scenes
Metastatic disease to the CNS
Parenchymal brain metastasesSeveral abstracts were presented regarding brain metastasis. Most notable was a large retrospective series of patients (n = 777) treated with surgery followed by wholebrain irradiation (WBI) or WBI alone [1]. Outcome was determined to be dependent upon recursive partitioning ana lysis class, graded prognostic assessment class, performance status and tumor histology. The best outcome was seen in breast cancer brain metastases. From the same institution, 329 patients with one or two brain metastases were retrospectively evaluated for outcome, comparing surgery followed by WBI and a stereotactic radiotherapy boost (SRB) versus WBI and, in responding patients, a SRB [2]. The group treated by surgery followed by WBI and SRB resulted in the best outcome and breast cancer-derived metastases benefited most from WBI and SRB.
Leptomeningeal diseaseA study from Spain demonstrated the safety of intra-cerebrospinal fluid (CSF) chemotherapy as determined by the incidence of treatment-related side effects. Furthermore, the study noted that side effects were disproportionately higher in patients treated by a ventricular access device or in those patients receiving intra-CSF liposomal cytarabine [3]. Another study from Spain utilized CSF flow cytometry and a monoclonal antibody directed against epithelial cell adhesion molecule in patients with carcino matous meningitis and determined a 75% detection rate of malignant cells in the CSF [4]. The authors postulate tumor burden, as determined by the proportion of positive cells, has survival implications.
CONFERENCE SCENEA selected review of abstracts from the 10th Congress of the European Association of Neuro-Oncology Marc C Chamberlain* 10th European Association of Neuro-Oncology, Marseille, France, 6-9 September 2012The European Association of Neuro-Oncology (EANO) is the largest neurooncology meeting in Europe. It meets biannually and reproducibly provides an exciting forum to present new brain cancer clinical trials and research data. The EANO 2012 meeting comprised 3 days of presentations; nearly 80 oral presentations and over 350 abstracts, providing a contemporary overview of neuro-oncology that includes both metastatic diseases of the CNS as well as primary brain tumors. This article attempts to highlight select abstracts presented at this year's meeting in a short review that provides a portrait of a large and multifaceted meeting.